Prioritize your health and safety
Missed periods lasting three or more months, heavy bleeding, or intermenstrual spotting should prompt a GP review, and pregnancy should always be excluded
SELECT Trial The SELECT trial, one of the largest cardiovascular outcomes trials in obesity medicine, enrolled over 17,000 participants with established cardiovascular disease and obesity or overweight (without diabetes) and demonstrated a 20% reduction in MACE with semaglutide 2.4 mg
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
&srotate=0)
)
)
